Bio-Techne Corporation is currently facing significant challenges, including disappointing earnings and growing concerns over the effects of artificial intelligence on its growth prospects. Despite these setbacks, UBS analyst Dan Leonard has reiterated a 'buy' rating while lowering the target price to $62, and the company's stock emerged as one of the top performers in the S&P 500 recently. As Bio-Techne continues to pursue an aggressive acquisition strategy, its market capitalization stands at approximately $6.78 billion, indicating resilience amid financial pressures.
“Bio-Techne Corporation · has faced · recent challenges · disappointing earnings and concerns over AI's impact on growth”
“Bio-Techne Corporation · was incorporated in · 1976”
“Bio-Techne Corporation · changed its name to · Bio-Techne Corporation · in November 2014”
“Bio-Techne Corporation · has total employees · 3,100”
“Bio-Techne · provides · products, tools, and scientific partnership · to test ideas, replicate results, and prove the impossible”
“Bio-Techne · improves · quality of life worldwide · by catalyzing advances in science and medicine”
“Bio-Techne Diagnostic · delivers · quality controls, reagents, and assay development & manufacturing”
“Bio-Techne · is based in · Minnesota · true”
“Bio-Techne · supplies · consumables and instruments · for pharma, biotech, academic, and diagnostic markets”
“Bio-Techne · reports in segments · protein sciences and diagnostics and genomics · 75% and 25% of revenue respectively”
“Bio-Techne · has operations in · Europe, Middle East, Africa · 20%”
“Bio-Techne · has operations in · UK · 5%”
